Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jagsonpal Pharmaceuticals Ltd. ( (IN:JAGSNPHARM) ) has issued an update.
Jagsonpal Pharmaceuticals has allotted 176,900 equity shares with a face value of Rs. 2 each under its Employee Stock Option Plan, 2022, to eligible employees following the exercise of vested options. The new shares, issued at various exercise prices and ranking pari passu with existing equity, increase the company’s paid-up share capital from Rs. 13.39 crore to Rs. 13.43 crore, reflecting continued use of equity-based incentives to retain and motivate key staff while modestly diluting existing shareholdings.
Following this allotment, the total number of issued equity shares has risen to 67,139,150, all carrying identical rights and listing status on both BSE and NSE. The move underscores the company’s commitment to share-based employee benefits within the SEBI regulatory framework, signaling an emphasis on long-term alignment between employees and shareholders without imposing any lock-in on the newly issued stock.
More about Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Ltd. is an India-based pharmaceutical company whose equity shares are listed on BSE and the National Stock Exchange of India. The company operates in the healthcare and drug manufacturing sector, with a focus on developing and marketing pharmaceutical products for the domestic market.
Average Trading Volume: 11,522
Technical Sentiment Signal: Buy
Current Market Cap: 12.91B INR
For a thorough assessment of JAGSNPHARM stock, go to TipRanks’ Stock Analysis page.